Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Emergent BioSolutions clinical trials
The registry lists 51 studies whose lead sponsor is Emergent BioSolutions or one of 2 companies grouped under it. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
Keep track of what changes. Save the Emergent BioSolutions studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Emergent BioSolutions.
- Emergent BioSolutions47 studiesSame company
Something wrong?
- Cangene Corporation3 studies →Acquired — became part of Emergent BioSolutions, Feb 21, 2014 · source ↗
Something wrong?
- Emergent Product Development Seattle LLC1 study →Divested — left Emergent BioSolutions, Aug 1, 2016 · source ↗
Something wrong?
Focus areas
Conditions Emergent BioSolutions leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →
- VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionEnrolling by invitationNCT01374984
- Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot yet recruitingNCT07478471
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruitingNCT02177721Phase 4
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot yet recruitingNCT03569514
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot yet recruitingNCT03569553
- BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsEnrolling by invitationNCT02051062Phase 4
- Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Not yet recruitingNCT07268612
- CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaTerminatedNCT00893516Phase 2
- Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsCompletedNCT05377255Phase 1
- VELOCITY: An Anthrax Vaccine Clinical StudyCompletedNCT03877926Phase 3
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyCompletedNCT04067011Phase 2
- Ciprofloxacin BioThrax Co-Administration StudyCompletedNCT01753115Phase 2
- A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsCompletedNCT04661839Phase 1
- A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsCompletedNCT05142306Phase 1
- Study of SIAN Nasal Spray in Healthy AdultsCompletedNCT05194358Phase 1
- Universal Influenza A Vaccine in Healthy AdultsCompletedNCT05155319Phase 1
- Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCompletedNCT05935917Phase 1
- Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsCompletedNCT00679172Phase 2
- Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01491607Phase 3
- Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)CompletedNCT00928577
- Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsCompletedNCT00053482Phase 2
- Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)TerminatedNCT01311674Phase 3
- ACAM2000® Myopericarditis RegistryCompletedNCT01395082
- Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy SubjectsTerminatedNCT02696291Phase 1
- Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCompletedNCT01263691Phase 1
- Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)CompletedNCT03624946Phase 1
- Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ACompletedNCT03315104Phase 2
- Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelCompletedNCT01540929
- Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsTerminatedNCT02771730Phase 1
- VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVCompletedNCT01158157Phase 3
- A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047TerminatedNCT03160339Phase 1
- Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy SubjectsCompletedNCT02061358Phase 1
- VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVCompletedNCT02443623Phase 4
- A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCompletedNCT01770743Phase 2
- Safety Surveillance Study of ACAM2000® Vaccinia VaccineCompletedNCT00927719
- Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB MuscleCompletedNCT00636519Phase 1
- Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedCompletedNCT02339155Phase 4
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)CompletedNCT00845650Phase 1/2
- Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationCompletedNCT00053495Phase 2
- Safety Study of 7 Botulinum Antitoxin Serotypes Derived From HorsesCompletedNCT00360737Phase 1
- A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesCompletedNCT01979406Phase 1
- HuMax-CD4 in Non-Cutaneous T-Cell LymphomaCompletedNCT00877656Phase 2/3
- Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1CompletedNCT01006798Phase 1
- BioThrax® (Anthrax) Vaccine in Pregnancy RegistryCompletedNCT01653392
- Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)CompletedNCT01202695Phase 1
- BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum AntitoxinCompletedNCT02055183
- Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumCompletedNCT00448253Phase 1
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia BWithdrawnNCT02048111Phase 3
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions
- Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant PatientsCompletedNCT00722332Phase 4
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions
- Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella InfectionApproved for marketingNCT00338442
Sponsor listed in the registry: Cangene Corporation · First submitted before Cangene Corporation became part of Emergent BioSolutions